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Ectopic Cushing Syndrome (EAS) is a rare condition responsible for about 5–20% of all
Cushing syndrome cases. It increases the mortality of affected patients thus finding and
removal of the ACTH-producing source allows for curing or reduction of symptoms and
serum cortisol levels. The aim of this study is to present a 20-year experience in the diagno-
sis and clinical course of patients with EAS in a single Clinical Centre in Southern Poland as
well as a comparison of clinical course and outcomes depending on the source of ectopic
ACTH production–especially neuroendocrine tumors with other neoplasms.
Methods
Twenty-four patients were involved in the clinical study with EAS diagnosed at the Depart-
ment of Endocrinology between years 2000 and 2018. The diagnosis of EAS was based on
the clinical presentation, hypercortisolemia with high ACTH levels, high dose dexametha-
sone suppression test and/or corticotropin-releasing hormone tests. To find the source of
ACTH various imaging studies were performed.
Results
Half of the patients were diagnosed with neuroendocrine tumors, whereby muscle weak-
ness was the leading symptom. Typical cushingoid appearance was seen in merely a few
patients, and weight loss was more common than weight gain. Patients with neuroendocrine
tumors had significantly higher midnight cortisol levels than the rest of the group. Among
patients with infections, we observed a significantly higher concentrations of cortisol 2400
levels in gastroenteropancreatic neuroendocrine tumors. Chromogranin A correlated signifi-
cantly with potassium in patients with neuroendocrine tumors and there was a significant
correlation between ACTH level and severity of hypokalemia.
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Conclusion
EAS is not common, but if it occurs it increases the mortality of patients; therefore, it should
be taken into consideration in the case of coexistence of severe hypokalemia with hyperten-
sion and muscle weakness, especially when weight loss occurs. Because the diagnosis of
gastroenteropancreatic neuroendocrine tumor worsens the prognosis-special attention
should be paid to these patients.
Introduction
Hypercortisolemia and a set of symptoms caused by it is defined as Cushing Syndrome (CS).
In most cases the source of CS lies in the excessive administration of glucocorticoids for vari-
ous medical reasons [1]. As regards endogenous causes, they are divided into two groups: adre-
nocorticotropic hormone (ACTH)-dependent and ACTH-independent CS, responsible for
about 70–80% and 20–30% of cases respectively [2]. Adenoma of the pituitary gland producing
ACTH—Cushing disease (CD) is the most common source of endogenous hypercortisolemia,
which accounts for about 60–70% of all CS cases [3] whereas less common are adenomas of
the suprarenal gland—a condition known as ACTH-independent CS (10–20% of all CS
patients) [2].
Ectopic Cushing Syndrome (EAS) is a rare condition, responsible for about 5–20% of all
(CS) cases and ca. 10–20% of ACTH-dependent CS patients [2, 4–11]. The first time when
EAS was named and largely studied was in the early 1960s by Liddle and soon after by Meador
[12, 13]. It plays a pivotal role to extract the group of EAS patients from all CS patients due to a
different management. Removal of the ACTH-producing source allows for curing or a signifi-
cant reduction of symptoms and serum cortisol levels. It is crucial to be active in searching for
the tumor that produces ACTH; some malignant, aggressive tumors could be hidden behind it
and failure to recognize it could result in poor prognosis [8, 14, 15]. In most cases the source of
ectopic production of ACTH is located in the lungs and mediastinum, but it can also be pro-
duced by tumors originating from other parts of the body, such as gastroenteropancreatic neu-
roendocrine tumors (GepNETs), pheochromocytomas and other [4].
The objective of this study is to present 20-year experience in the diagnosis and prognosis
of patients with EAS in a single Clinical Centre in Southern Poland. To the best of our knowl-
edge, this is the first work on the Polish population of patients with EAS, studying diagnostics
and clinical course depending on the type of tumor producing ACTH. We aimed to analyze
the course of EAS in NET and especially in GepNET patients, compared to other locations.
Methods
We retrospectively reviewed the records of patients with EAS diagnosed at the Department of
Endocrinology between 2000 and 2018 and reviewed the records for routine (but typical for
CS) and endocrine biochemical tests: ACTH was measured by immunoradiometric assay
(Brahms, Henningsdorf, Germany), whereas plasma cortisol was measured by electrochemilu-
minescence method (Roche Diagnostics GmbH, Mannheim, Germany).
To find the source of ACTH, biochemical parameters were checked (chromogranin A, cal-
citonin, 5-hydroxyindoleacetic acid (5-HIAA), urine metabolites of catecholamines)) carcino-
embryonic antigen (CEA) and cancer antigens: Ca 125, Ca 19–9 Ca 15–3, with various
imaging studies: anatomical: ultrasound of the abdomen (US), computed tomography (CT),
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magnetic resonance imaging (MRI) and functional: positron emission tomography with flu-
deoxyglucose (FDG-PET) and/or somatostatin receptor scintigraphy (SRS) were performed.
The diagnosis of EAS was based on the clinical presentation, hypercortisolemia with high
ACTH levels, high-dose dexamethasone suppression test (HDDST) and/or corticotropin-
releasing hormone (CRH) tests, because bilateral inferior petrosal sinus sampling (BIPSS) was
not available—mostly due to poor condition of the patients. Based on imaging techniques (CT
or MR), visible pituitary focal lesions were excluded as a cause of high level of ACTH.
Statistical methods
Statistical analysis was performed using STATISTICA 13.1 software (StatSoft, Inc., Tulsa,
USA). The data normality distribution was assessed using the Kruskal–Wallis test with the Lil-
liefors correction. Non–parametric tests were applied due to rejection of the normality hypoth-
esis for most of the analyzed parameters. The level of significance for all tests was set at 0.05.
The differences in median values were tested using the Mann–Whitney U test. Differences in
the number of patients, categorized by any criteria defined in this study, were tested using a
contingency table and the results were assessed based on a chi–square test with the Yates cor-
rection. The Kaplan–Meier plot and Cox proportional hazards model with FCox statistics
were used to assess differences in mortality in patients dichotomized by any criteria in this
study, where patients who were alive were classified as censored observations. The Spearman
correlation was used to test the relationship between the parameters and logistic regression
was used to prepare a model for predicting mortality. The selection of significant predictors
was based on the probability of the likelihood–ratio statistic. Finally, statistical significance was
assessed using the CHI2 test for the overall model and the Wald test statistics for the
predictors.
Ethics statement
The study was approved by the Bioethics Committee of the Jagiellonian University (reference
no.: 1072.6120.213.2019) and was performed in accordance with the ethical standards as laid
down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical
standards. Prior to performing any procedure, and after obtaining comprehensive informa-
tion, each patient signed informed consent, which is included in the patient’s medical history.
Results
Twenty-four patients with EAS were involved in the study: 14 women and 10 men (female to
male ratio 1.4:1), with a median age at the time of the diagnosis being 61 years.
Persistent hypokalemia with high suspicion of hypercortisolism was the reason for referral
to our Clinical Center in most of the cases. Merely 8 patients presented a typical cushingoid
feature and one patient has previously been treated for Guillain-Barre syndrome (due to sud-
den onset of muscle weakness). Half of the patients were diagnosed with neuroendocrine neo-
plasms– 6 females and 6 males (GepNETs, thymic and pulmonary carcinoids); among non-
NET patients, two were found with pheochromocytoma, one with esthesioneuroblastoma, two
with medullary thyroid carcinoma, two with carcinoma of the ovary, while the remaining
patients—with single small-cell lung carcinoma (SCLS), papilloma of the maxillary sinus and
adenocarcinoma of the stomach. In two patients in terminal state, who were only palliative
treated, although the potential source of ACTH was found (tumor of the pancreas and lung in
imagining studies), tissue specimen for histopathological examination was not available.
Table 1.
The most common clinical findings are shown in Table 2.
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There were no significant gender differences in clinical presentation, although there was a
higher percentage of hypertension and peripheral oedema in females, while facial plethora and
psychiatric disorders were more common in males. In general, muscle weakness was the lead-
ing symptom and typical cushingoid appearance (facial plethora, easy bruising, redistribution
of fat tissue, weight gain and hirsutism) was present in merely a few patients, most likely in
NET individuals. Weight loss was more prevalent than weight gain (11 vs 7 patients). Redistri-
bution of the fat tissue characteristic for cushingoid appearance and peripheral oedema were
considerably more common in NET patients (p = 0.041). Facial plethora was present in 13
patients (8 being NET patients) whereas easy bruising was seen in more than 50% of patients
(in 13 of 24); in this group, 9 patients had NET. Clinical data on osteoporosis was available
only in 9 cases: in 7 osteoporosis was diagnosed (in 5 patients with NET, and in single cases of
carcinoma of the ovary and tumor of the lung). Diabetes or a pre-diabetic state were present in
75% of patients (18 of 24), 10 being NET patients.
As regarding infections—they were documented in 16 patients (7 GepNET, 1 pheochromo-
cytoma, 1 esthesioneuroblastoma, 1 thymic carcinoid, 1 SCLC, 1 pulmonary carcinoid, 1 ovar-
ian carcinoma, 1 medullary carcinoma, 1 papilloma and 1 lung tumor). 8 of them had an
infection in more than 1 anatomic site. Table 3.
Table 1. Patients‘characteristics.
Patient No. Age (years)1 Gender Tumor Metastases Outcome
1 32 F Pancreatic NET + Deceased
2 42 M Thymic carcinoid + Deceased
3 32 M Pancreatic NEC + Deceased
4 55 M SCLC + Deceased
5 60 M Gastric NEC + Deceased
6 59 M Pulmonary carcinoid - Alive
7 62 F Ovarian carcinoma + Deceased
8 70 F Pheochromocytoma - Deceased
9 44 M Esthesioneuroblastoma - Alive
10 67 F Pancreatic NEC + Deceased
11 38 M Colon NET na Deceased
12 14 M Medullary thyroid carcinoma + Deceased
13 76 F Maxillary sinus papilloma - Alive
14 61 F Pheochromocytoma - Alive
15 78 F Ovarian carcinoma + Deceased
16 61 F Pancreatic NET + Deceased
17 47 F Pancreatic NET + Deceased
18 66 F Pancreatic tumor 2 + Deceased
19 85 F Lung tumor2 - Deceased
20 61 F Pulmonary carcinoid - Alive
21 65 F Gastric adenocarcinoma + Deceased
22 65 F Pancreatic NET + Deceased
23 49 M Medullary thyroid carcinoma + Alive
24 71 M Ileum NET + Deceased
Abbreviations: F-female; M- male; na-not available; NET- neuroendocrine tumor; NEC- neuroendocrine carcinoma;
SCLC-small cell lung carcinoma; + positive;—negative.
1at the time of diagnosis
2 no histopathological specimen with staining for ACTH available
https://doi.org/10.1371/journal.pone.0242679.t001
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Patients with infections were treated based on the antibiogram results when available, in
other cases- empiric therapy was applied in accordance to official and local antimicrobial pol-
icy. Individuals with infections had higher cortisol 0600 and 2400 concentrations than those
without it, although this did not reach statistical significance (p>0.05), what is more, among
patients with infections, we observed significantly higher concentrations of cortisol 2400 levels
in NET (p = 0.002) and GepNET (p = 0.046) patients. Fig 1a–1c.
Table 4 presents the most essential laboratory evaluations.
Not surprisingly, most of the patients had low TSH levels with a median concentration of
0.36 mIU/ml (in 21 of 24 it was lower than 1.0mIU/ml, 1 patient had TSH level of 3.23mIU/
ml, for the remaining 2 there was no data) and he range of sodium (Na) concentrations varied
from 135mmol/l up to 153 mmol/l (median—145mmol/l). In 15 patients from our group, we
measured the acid-base balance. Among 10 patients with metabolic alkalosis, 9 were hypokale-
mic, while on the other hand, correct acid-base balance was observed only in normokalemic
patients.
All subjects had elevated morning serum cortisol levels and midnight plasma cortisol levels,
with a median morning and midnight plasma cortisol level 1655.17 nmol/l and 1434.48 nmol/l
respectively. Twenty of 24 patients had lost their cortisol circadian rhythm, whereby of the
remaining 4, all were non-NET female patients, with lung tumor, papilloma, gastric
Table 2. Clinical symptoms.
total group female Male
Clinical features n (% of
patients)
N = 24
NET n = 12 (%
of patients)
non-NET n = 12
(% of patients)
p NET n = 6 (%
of patients)
non-NET n = 8
(% of patients)
p NET n = 6 (%
of patients)
non-NET n = 4
(% of patients)
p
Muscle weakness 21 (88) 10(83) 11(92) n.s. 5(83) 8(100) n.
s.
5(83) 3(75) n.s.
Hypertension 19 (79) 9(75) 10(83) n.s. 5(83) 7(88) n.
s.
4(67) 3(75) n.s.
Infections 16 (66) 9(75) 7(58) n.s. 4(67) 4(50) n.
s.
5(83) 3(75) n.s.
Peripheral oedema 15 (63) 10(91) 5(42) 0.041 6(100) 4(50) n.
s.
4(67) 1(25) 0.170
Facial plethora 13 (54) 8(67) 5(42) n.s. 2(33) 3(38) n.
s.
6(100) 2(50) n.s.





12 (50) 9(75) 3(25) 0.041 4(67) 2(25) n.
s.
5(83) 1(25) n.s.










9 (38) 5(42) 4(36) n.s. 3(50) 3(38) n.
s.
2(33) 1(25) n.s.
Weight gain 7 (29) 4 (33) 3(25) n.s. 1(17) 2(25) n.
s.
3(50) 1(25) n.s.
Hirsutism1 6 (46) - - - - - - - - - 4(67) 2(29) n.
s.
- - - - - - - - -
Striae 3 (13) 2(17) 1(8) n.s. 0(0) 0(0) - - - 2(33) 1(25) n.s.
1only female patients
Abbreviations: NET- neuroendocrine tumor; n.s—non-statistically significant
https://doi.org/10.1371/journal.pone.0242679.t002
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adenocarcinoma, and ovarian carcinoma. The range of basal plasma ACTH levels varied from
14.74 up to 312.62 pmol/l, with median 70.4 pmol/l (all were above the upper limit; with a ref-
erence range 1.32–12.33pmol/l). All patients showed an incorrect response in dynamic tests
(LDDST, HDDST, CRH test). Table 4 also shows that the majority of patients suffered from
hypokalemia with median potassium (K) concentrations 2.65mmol/l, which affected 17 of 24
individuals (70%; all but one had potassium levels lower than 3.0 mmol/l). However, all
patients had an evidence of prior hypokalemia in medical history. Furthermore, there was a
Table 3. Characteristics of infections in EAS patients.
Site No. of patients Number of patients with infection/ Pathogen




• oral cavity 2 1.Cryptoccocus laurentii,
1.na
• esophagus 2 1.Candida albicans
1. fungal infection
• small intestine 1 1.Rotavirus
• liver-AVH 1 1. Hepatitis B and C virus
Urinary tract 6 1.Enterococcus faecalis, Streptoccocus viridans
1.Enterococcus faecalis VRE
2.Escherichia coli




• otitis media 1 1.na







• bacterial conjunctivitis 1 1.na
Postoperative wound 3 1.Serratia marcescens, Morganella morgani
1.Staphylococcus epidermidis
1. Escherichia coli ESBL
Central nervous system 1 1.na
Other
• coxitis fugax 1 1.na
• suprahepatic abscess 1 1.na
• abscess in the bursa omentalis 1 1.Enterobacter cloacae ESBL
• sepsis 2 1. Escherichia coli
1.Klebasiella pneumoniae ESBL, Escherichia coli
Abbreviations: na- not available; VRE—Vancomycin-resistant enterococci, HLAR—High-level aminoglycoside
resistance; ESBL—Extended spectrum beta-lactamases; AVH—Acute viral hepatitis
https://doi.org/10.1371/journal.pone.0242679.t003
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significant correlation between ACTH level and severity of hypokalemia (p<0.05) despite the
source of EAS. Table 5.
We found that ACTH was significantly positively correlated with Na and negatively corre-
lated with phosphate in EAS patients without NET, whereas there was not any substantial cor-
relation of those electrolytes in patients with NET. Moreover, ACTH considerably negatively
correlated with K both in EAS patients with and without NET (as mentioned above). Chromo-
granin A correlated significantly with K (positively) in EAS patients with NET. EAS patients
who died had significantly higher values of early morning cortisol levels (n = 18; 1779.31±
468.97 [nmol/l]) than patients, who survived (n = 6; 1020.69± 965.52 [nmol/l]): p = 0.028) and
Fig 1. a. Cortisol 0600 and 2400 in patients with (1) and without (2) infections. b. Cortisol 0600 and 2400 in NET (1)
and non-NET (2) patients with infections. c. Cortisol 0600 and 2400 in GepNET (1) and non-GepNET (2) patients
with infections.
https://doi.org/10.1371/journal.pone.0242679.g001
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when assessing patients with and without NET, we observed a significantly higher concentra-
tion of midnight cortisol levels (cortisol 2400) in NET patients (p = 0.024). Table 6.
Furthermore, when assessing patients with different localizations of neuroendocrine
tumors separately, those diagnosed with GepNET had statistically higher cortisol 2400 concen-
trations than non-GepNET patients (median 1765.52 nmol/l and 827.59nmol/l, respectively;
p = 0.008). Moreover, GepNET patients had higher ACTH concentrations (median
75.95pmol/l; IQR 41.84pmol/l) than mediastinal NETs (mNETs) (median 45.80 pmol/l; IQR
29.94pmol/l) and other tumors (median 58.03 pmol/l; IQR 51.92pmol/l) and higher cortisol
0600 concentrations and lower potassium levels, although this did not reach statistical signifi-
cance. Table 7.
The levels of ACTH did not vary (p = 0.37) in patient with and without distant metastases
(median 75.64 pmol/l; IQR 58.30pmol/l vs 45.80 pmol/l; IQR 37.44pmol/l), although if outliers
are omitted (1421pg/ml in one case of esthesioneuroblastoma without metastases), the
Table 4. Data of all EAS patients.
Total group Female Male
Parameter /reference range Med(Q1-Q3) Range Med(Q1-Q3) Range Med(Q1-Q3) Range
K /3.50–5.10 mmol/l 2.65 (2.02–3.67) 1.61–4.90 2.45 (1.95–3.42) 1.61–4.90 2.81 (2.43–4.24) 1.70–4.62
Na /136.00–145.00 mmol/l 145.00 (142.00–148.93) 135.00–153.00 145.00 (141.50–149.25) 135.00–153.00 145.10 (142.00–149.03) 138.00–151.00
Ca /2.15–2.55 mmol/l 2.12 (1.94–2.31) 1.37–3.18 2.20 (2.04–2.32) 1.65–2.42 2.00 (1.92–2.29) 1.37–3.18
P /0.81–1.45 mmol/l 0.94 (0.69–1.18) 0.42–1.86 0.94 (0.69–1.16) 0.42–1.53 0.92 (0.66–1.26) 0.59–1.86























cortisol 0600 h:2400 h ratio
/>2.0
1.09 (1.09–1.73) 0.83–4.63 1.48 (1.04–2.39) 0.88–4.63 0.98 (0.93–1.10) 0.83–1.31
ACTH /1.32–12.33 pmol/l 70.40 (34.10–88.40) 14.74–312.62 66.00 (36.30–88.66) 14.70–153.56 70.40 (29.48–86.68) 15.40–312.62
Abbreviations: Med-median; Q1-first quartile; Q3-third quartile; range-minimum to maximum range; cortisol 0600- early morning cortisol; cortisol 2400- midnight
cortisol ACTH—adrenocorticotropic hormone; K—potassium; Na—sodium; Ca—calcium; P—phosphate; TSH—thyroid-stimulating hormone.
https://doi.org/10.1371/journal.pone.0242679.t004
Table 5. Correlation between ACTH, cortisol, chromogranin A and electrolytes in EAS patients.
electrolyte NET non-NET
n = 12 n = 12
R Spearman p-value R Spearman p-value
ACTH Na n.s. 0.830 < 0.001
K –0.606 0.037 –0.634 0.027
P n.s. –0.606 0.048
cortisol 0600 K n.s. -0.697 0.025
cortisol 2400 Na n.s. 0.918 < 0.001
CgA K n.s. 0.019 n.s.
Abbreviations: NET- neuroendocrine tumor; ACTH—adrenocorticotropic hormone; cortisol 0600—early morning cortisol; cortisol 2400 –midnight cortisol; Na—
sodium; K—potassium; P–phosphate; CgA—Chromogranin A; n.s—non-statistically significant
https://doi.org/10.1371/journal.pone.0242679.t005
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differences become more apparent, though still not significant (75.64 pmol/l; IQR 58.30pmol/l
vs 41.95 pmol/l; IQR 24.06 pmol/l in cases without metastases; p = 0.13).
Concerning other laboratory findings: serum calcitonin was elevated in both patients with
medullary thyroid cancer, while chromogranin A was elevated in 6 patients: in 4 patients with
NET (2 with pulmonary carcinoid and 2 with pancreatic NET) and 1 with pheochromocytoma
Table 6. Data of patients with and without NET.
total group female male
NET n = 12 non-NET n = 12 p NET n = 6 non-NET n = 8 p NET n = 6 non-NET n = 4 p
K mmol/l 2.65 (2.40–2.81) 2.93 (1.90–3.92) n.
s.
2.40 (1.97–2.50) 2.93 (2.00–4.09) n.
s.
2.81 (2.72–4.50) 2.80 (1.80–3.92) n.s.

















Ca mmol/l 2.12 (2.00–2.31) 2.16 (1.83–2.31) n.
s.
2.16 (2.11–2.20) 2.25 (1.89–2.32) n.
s.
2.00 (1.94–2.42) 2.01 (1.64–2.19) n.s.
P mmol/l 0.90 (0.71–1.21) 0.94 (0.66–1.15) n.
s.
0.94 (0.71–1.18) 0.91 (0.76–1.04) n.
s.
0.85 (0.75–1.21) 0.99 (0.59–1.27) n.s.
TSH mIU/ml 0.31 (0.11–0.55) 0.38 (0.19–0.70) n.
s.
0.21 (0.03–0.40) 0.45 (0.14–0.80) n.
s.
0.37 (0.15–0.70) 0.29 (0.20–0.38) n.s.











































cortisol 0600 h:2400 h
ratio
1.03 (0.98–1.48) 1.23 (1.04–2.80) n.
s.
1.34 (0.98–1.70) 1.78 (1.11–3.33) n.
s.
1.00 (0.97–1.12) 0.94 (0.92–0.95) n.s.
Testosterone ng/ml 2.50 (2.00–4.00) 4.50 (2.00–7.00) n.
s.
2.00 (2.00–3.00) 3.00 (1.50–5.50) n.
s.
4.00 (2.00–4.00) 12.50 (5.00–20.00) n.s.

















CgA nmol/l 22.50 (4.00–51.00) 5.00 (5.00–12.00) n.
s.




- - - - - - - -
Abbreviations: K—potassium; Na–sodium; Ca-calcium; P–phosphate; TSH—thyroid-stimulating hormone; ACTH—adrenocorticotropic hormone; cortisol 0600—early
morning cortisol; cortisol 2400 –midnight cortisol; CgA—Chromogranin A; n.s—non-statistically significant;
�p = 0.024
https://doi.org/10.1371/journal.pone.0242679.t006
Table 7. Data of patients with and without GepNET.
Parameter GepNET non-GepNET p
n = 9 n = 15
Med (Q1-Q3) Med (Q1-Q3)
ACTH (pmol/l) 75.95 (66.06–107.91) 56.15 (34.13–85.11) 0.34
cortisol 0600 (nmol/l) 1958.62 (1655.17–2041.38) 1655.17 (1089.65–1820.69) 0.13
cortisol 2400 (nmol/l) 1765.62 (1600.00–1986.20) 827.59 (551.72–1517.24) 0.01
K (mmol/l) 2.60 (2.40–2.72) 2.80 (2.00–3.92) 0.47
Abbreviations: GepNET- gastroenteropancreatic neuroendocrine tumor; Med-median; Q1-first quartile; Q3-third
quartile; Cortisol 0600- early morning cortisol; cortisol 2400- midnight cortisol ACTH—adrenocorticotropic
hormone; K–potassium.
https://doi.org/10.1371/journal.pone.0242679.t007
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and 1 with ovarian carcinoma. For 6 NET patients and for 7 non-NET patients there was no
data.
Radiological data of the patients is presented in Table 8.
In most cases, a single imaging study allowed to detect the primary change: In 2 patients,
MRI was the first-choice examination, and it was positive, whereas CT was performed in 22
patients, giving a negative result in 4. MRI examination revealed a source of ectopic ACTH in
one case. Among 3 patients with negative both CT and MRI–in 2 SRS or FDG-PET revealed a
lesion, while the last one had positive ultrasound examination. Concerning CT, hyperplasia of
the adrenal glands (AH) was present in 75% of our patients (18 of 24); no data was available
for one patient.
In our study, 10 patients diagnosed as NET underwent SRS, in all of those, we observed a
high uptake of radionuclide in lesions producing ACTH. Five patients with NET underwent
FDG-PET, which was positive. SRS performed in 7 non-NET patients was positive only in 4
cases–all with diffused neuroendocrine system—derived tumors (2 pheochorocytomas, one
Table 8. Radiological data of EAS patients.
NET CT 1 MRI1 Scintigraphy FDG PET/CT
Patient No. Done Revealed change Done Revealed change Done Revealed change Done Revealed change
1 + + + na na + + - -
2 + + + na na + + - -
3 + + + na na + + + +
4 - + + na na na na na na
52 + + + na na na na na na
6 + + + na na + + + +
73 - + + - - + - + +
8 - - - + + + + + +
9 - + - - - + + na na
10 + + + - - + + na na
11 + + - - - + + na na
124 - + - - - na na na na
13 - + + + - + - + +
14 - + + - - + + na na
15 - + + - - - - + +
16 + - - + + - - + +
17 + + + - - + + - -
18 - + + - - na na na na
19 - + + - - - - + +
20 + + + - - + + + +
21 - + + na na + - + +
225 + + - + + + + + +
23 - + + - - + + + +
24 + + + na na + + na na
1conducted in any area of the body;
2tumor revealed in gastroscopy before CT performed;
3 CT together with PET;
4 tumor revealed in the ultrasound of the neck;
5CT did not reveal tumor of the pancreas
https://doi.org/10.1371/journal.pone.0242679.t008
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esthesioneuroblastoma, 1 medullary thyroid carcinoma) confirmed in FDG-PET. In three
non-NET patients SRS was negative, while increased glucose metabolism in pathological struc-
tures was revealed in the FDG-PET. In 2 patients (ovarian carcinoma and lung tumor), CT
(abdominal, pelvic and chest) showed a tumor suspected of malignancy.
In 18 patients MRI of the pituitary was conducted in order to exclude visible pathological
mass of the pituitary area.
Concerning treatment, tumor responsible for ectopic secretion was resected in 12 patients
(in 2 surgery was not radical), in all patients who underwent radical tumorectomy, the signs
and symptoms of Cushing’s syndrome resolved and normalization of cortisol and ACTH levels
was observed. Adjuvant treatment included: chemotherapy (1/24), radiotherapy (2/24), Pep-
tide Receptor Radionuclide Therapy (PRRT) and treatment with long-acting somatostatin
analogue for all NET patients. To control hypercortisolemia, adrenal steroidogenesis inhibitors
(ketoconazole, metyrapone, mitotane) were used. Three patients underwent only palliative
treatment due to a poor general condition and two patients: one with MTC and one with thy-
mic NET, underwent bilateral adrenalectomy.
Of the whole group of patients, 18 died, most due to widely disseminated disease. Table 1.
Among them one patient with co-existing viral hepatitis C died with the symptoms of acute
liver failure due to rapid hypercortisolemia and three patients due to complications after sur-
gery; the median duration of follow-up was 8.5 months (range-1-86 months; with a median
survival of 9.7 months). Patients diagnosed with GepNET had higher mortality compared to
the rest of the group, despite targeted treatment-those were the patients who, at the time of
diagnosis of EAS, already had disseminated disease, or had been treated with long-acting
somatostatin analogs for many years until progression synchronous with the appearance of
EAS. Fig 2.
Similarly, the presence of metastases significantly worsened the probability of survival. Fig 3.
Discussion
EAS is a rare disease whose incidence rate is 1 up to 3 new cases/1 million people/year [1, 3–5,
11]. However, if it occurs increases the mortality of patients [8, 15, 16]. It is well known, that
hypercortisolemia itself increases the mortality of affected patients. In recently published
Fig 2. Survival analysis based on type of tumor. The difference in mortality in patients with and without
neuroendocrine tumors of the gastrointestinal tract.
https://doi.org/10.1371/journal.pone.0242679.g002
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series, Davi et al. confirmed that the severity of cortisol excess impacts on survival [14]. In our
work, patients who died had significantly higher cortisol concentrations than patients who
survived.
During our research we focused on EAS in the course of NET and non-NET tumors. We
did not compare CD with EAS, but presented a group of patients with EAS focusing on the dif-
ferences between the course of EAS in NET and non-NET. To our knowledge, no work on the
subject has been published so far.
The major finding of our work is the fact that NET and especially GepNET is a special
group of EAS patients. As more and more patients with GepNET are being diagnosed recently,
more and more EAS cases in the course of NET will appear.
In our study, compared to other tumors, NETs had higher ACTH and cortisol concentra-
tions with lower potassium and TSH levels. Our data are in contrast to those analyzed by Isi-
dori, where NET patients had lower cortisol and ACTH concentrations [4].
Furthermore, when analyzed the GepNET subgroup versus the rest of the tumors -the dif-
ferences were the highest.
This could be the explanation of another important finding of our study—that GepNET
patients have significantly worse overall survival compared with patients with different source
of EAS. GepNET patients usually have distant metastases at initial diagnosis [17]. In our
group, all GepNET patients had disseminated disease at the time of the diagnosis. On the other
hand, it can be partly explained by the fact that the non-GepNET group includes patients with
poor prognosis such as carcinomas (ovary, lung, stomach) as well as those with better progno-
sis such as medullary thyroid carcinoma, pheochromocytoma, esthesioneuroblastoma and
patients with lung carcinoid tumors.
ACTH and CRH can be produced by almost all tumors, both malignant and benign, of
endocrine and non-endocrine origin [3, 18–23]. In the last decades, we have observed a shift
in the prevalence in EAS to more often diagnosed neuroendocrine tumors [8, 19, 23, 24]. Most
cases in the first decades after establishing the definition of EAS were caused by small cell lung
carcinoma [12, 13, 23]. Still, almost half of the tumors can be found in the thoracic cavity,
mostly bronchial carcinoids and SCLCs [4, 8, 11, 24–26]. In our study, on the contrary, most
were located in the abdomen or pelvis. Compared with other large studies we observed a
higher proportion of GepNETs (37.5% vs 3.0–18.3%) [3, 4, 9, 14, 15, 17, 21, 26]. Table 9.
Fig 3. Survival analysis based on type of tumor. The difference in mortality in patients with and without metastases.
https://doi.org/10.1371/journal.pone.0242679.g003
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This can be partly explained by the fact that in our medical center, we mostly diagnose and
treat endocrinological disorders, whereas most patients with SCLC are under care in oncologi-
cal centers. Another explanation for the different percentage distribution of tumors in our
study could be the fact, that those patients do not have time to develop typical cushingoid fea-
ture and severe hypokalemia is usually treated symptomatically, without any further diagnostic
procedures. Typical cushingoid features are more often seen in latent tumors, compared to
malignant neoplasms—in those cases, due to the rapid progression of the underlying disease,
typical symptoms of hypercortisolemia may not be revealed. Symptoms of hypercortisolism
often appear in advanced stages of non-NET patients, especially in SCLC, when cachexia and
electrolyte disturbances dominate which are related to the terminal state of the patient or treat-
ment. Concerning neuropsychiatric disorders (observed in 42% of patients in our group) they
are not common in EAS patients, most likely due to a poor general condition, though is some
cases it can be the leading symptom of ectopic ACTH production [27–29].
What is more, there was a higher female to male ratio in our study, in contrary to other
analyses where there is a male predominance in EAS; probably because most lung cancer
patients are males, while GepNET patients are predominantly women [25, 30].
Furthermore, compared to CD, EAS patients are more likely to experience severe hypokale-
mia, which has been previously broadly studied—the higher the plasma cortisol concentration,
the more severe the hypokalemia [14, 25, 31]. Hence, our results are similar. The authors of
these earlier publications have proposed an explanation for this phenomenon. They suggested
that excessive production of cortisol induces a state in which cortisol itself acts as a mineralo-
corticoid, regardless of ACTH, saturating the 11beta-hydroxysteroid-dehydrogenase [25]. In
comparison to other series- our group had similar prevalence of hypokalemia (70%).
Concerning infections in EAS patients: it is well known that high level of cortisol predispose
to infections [32–34]. We have found interesting correlation between the level of hypercortiso-
lemia, predisposition to infections and primary site of tumor responsible for EAS. NET and
Table 9. Tumors associated with EAS in our study and previously published series.















Mean ± SD 45.9
±15.3
Mean ± SD 37.6
±14.8




• Female 14 (58.0) 64 (58.2) 26 (60.5) 9 (56.2) 19 (50.0) 48 (53.3) 61 (57.5) 19 (67.6)
• Male 10 (42.0) 46 (41.8) 17 (39.5) 7 (43.8) 19 (50.0) 42 (46.7) 45 (42.5) 9 (32.4)
SCLC 1 (4.1) 4 (3.6) 9 (20.9) 2 (12.5) 7 (17.5) 3 (3.3) 12 (11.3) -
Bronchial carcinoids 2 (8.3) 45 (40.9) 9 (20.9) 3 (18.7) 12 (30.0) 35 (38.8) 26 (24.5) 11 (39.3)
GepNET 9 (37.5) 20 (18.2) 6 (14) 2 (12.5) 3 (7.5) 8 (8.8) 17 (16.0) 3 (10.7)
Other NET - - - - 4 (10.0) 13 (14.4) 8 (7.5) -
Thymic carcinoid 1 (4.1) 6 (5.5) 3 (6.9) 1 (6.2) 2 (5.0) 5 (5.5) 5 (4.7) 2 (7.1)
MTC 2 (8.3) 2 (1.8) 5 (1.6) - 3 (7.5) 2 (2.2) 9 (8.5) -
Pheo 2 (8.3) 7 (6.4) - - 1 (2.5) 5 (5.5) 3 (2.8) 3 (10.7)
Other 5 (20.8) 1 (0.9) 4 (9.3) 2 (12.5) 3 (7.5) 2 (2.2) - -
Unknown/Occult 2 (8.3) 25 (22.7) 4 (9.3) 6 (37.5) 5 (12.5) 17 (18.8) 17 (16.0) 9 (32.4)
Abbreviations: SCLC–small-cell lung carcinoma; GepNET–gastroenteropancreatic neuroendocrine tumor; NET—neuroendocrine tumor; MTC—Medullary thyroid
carcinoma; Pheo—Pheochromocytoma
https://doi.org/10.1371/journal.pone.0242679.t009
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GepNET patients (with worse prognosis of survival) with infections had significantly higher
levels of cortisol. As it was presented in previously reported research–the higher hypercortiso-
lemia, the higher prevalence of infections in affected patients [33].
Our study confirmed that, EAS patients most often had muscle fatigue and hypertension.
Similarly, proximal muscle weakness as the leading symptom in the case of hypercortisolemia
of ectopic origin is observed in studies from various centers [3, 11, 35–38]. Also well-known is
the influence of glucocorticoids on thyroid function (suppression of the hypothalamic-pitui-
tary-thyroid axis) [39–42]. Here, the assessment of TSH by primary care providers can be of
great value and practitioners should be aware, that in case of coexisting severe hypokalemia,
muscle weakness with low TSH (in patients with no history and signs of thyroid disorders) can
strongly suggest hypercortisolemia and EAS. We therefore propose that TSH may be a simple
blood test, which could improve the diagnosis of hypercortisolemia.
Concerning imagining techniques, in our work, in all cases the possible source of ectopic
ACTH was found in at least one of the imagining techniques. None of the single imaging stud-
ies give 100% sensitivity but combining different techniques allows to increase it [7, 43–47].
On top of that, because more and more cases of EAS origin from NETs, SRS begins to play an
increasingly important role, especially in the case of negative CT or MRI, and should be taken
into account at an early stage of the diagnostic algorithm [45, 48–52]. In EAS non-NET
patients with tumors originating from the diffused endocrine system-DES (as esthesioneuro-
blastoma, pheochromocytoma or medullary thyroid carcinoma), diagnostic procedures can be
based on SRS. In those patients, lesions localized in SRS were confirmed by other imaging
studies, similarly to NET patients. In other patients with tumors not originating from DES (as
carcinomas or papillomas), SRS seems to be of lower diagnostic significance. In those cases,
imaging procedures should first be based on CT, MR or FDG-PET. FDG-PET in NETs has a
much lower sensitivity in detecting the primary source of tumor [47, 48, 50, 53, 54]. As it was
explained by Adams et al., this is mostly due to its limited metabolic activity [55].
In general, hyperplasia of the adrenal glands (AH) is often seen in CS [56, 57]. In our work
it was observed in 18 patients (75%), these results are similar to those achieved by Imaki et al.,
where AH was seen in 75% patients (3 of 4) and in 54% of CD patients [56]. An even higher
frequency was reported by Sohaib et al. (90% in EAS patients (9 of 10) compared with 62% in
CD patients) [57]. What is common across all studies is that AH was more often seen in EAS
patients than in other causes of ACTH-independent CS–probably due to extremely high levels
of ACTH in those patients [17, 56, 57].
Confirmation of EAS is challenging. The gold standard in the diagnosis of EAS is BIPSS
and confirmation of EAS requires positive staining for ACTH or CRH in tumor cells [4, 10,
20, 54, 58]. In our patients, due to the poor condition of the patients, BIPSS was not available,
and in addition, when patients could not underwent tumorectomy, no immunohistochemical
evaluation was available.
Pituitary MR examination cannot be used to unequivocally exclude or confirm EAS,
because false negative results are also observed in pituitary CS–and it is an important limita-
tion of this method. HDDST, alone, is also of limited value [10]. However, the ACTH concen-
tration in all concerning EAS publications was shown to be significantly higher than in CD
patients. Aron in his article has focused on the value of HDDST in the diagnosis of ACTH—
dependent CS. He proved that the HDDST has limited value in the differentiation of the
source of ACTH—dependent CS. We fully agree with this statement. In our patients, it was
one of the tests that in combination with other laboratory tests and clinical presentation
allowed EAS to be suspected. What is more, in his publication, Aron showed that compared to
CD patients, EAS patients had significantly higher mean ACTH concentration (47 vs 17 vs.
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pmol/l), as well as a smaller percentage of patients who had suppression by 50% or more of the
baseline in HDDST (33.3 vs. 81.0%). Also MR imaging was not a differentiating criterion [10].
The source of ectopic ACTH is neoplastic tissue, which usually is confirmed in immunohis-
tochemistry examination. In our study, only in 3 patients immunohistochemistry staining in
the tumor tissue for ACTH was available: in two patients it was positive, and in the other one it
was negative. Concerning the last patient, as it was proposed by Isidori and Lenzi, only a sub-
population of cells may actually secrete ACTH which could explain our finding [4].
There are some limits to this study. Firstly, we mainly used archival data. Secondly, the
patients came from a single center focused on endocrine diseases. Most of them had at least
mild features of hypercortisolemia and/or signs of elevated ACTH. Patients with lung neo-
plasms are diagnosed and treated in Oncological Centers. Because IPSS considered as the diag-
nostic gold standard was not available, the diagnosis of EAS was based on laboratory findings,
clinical symptoms, imagining techniques and/or resolution of hypercortisolemia after removal
of the tumor responsible for EAS. The limitation of this study is also the fact that we failed to
distinguish between ectopic CRH and ACTH secretion. Thus, Muller et al. suggested that non-
excessive elevation of serum ACTH and a partial response to high-dose dexamethasone test
with negative imaging can imply the ectopic production of CRH [59].
Conclusions
1. The occurrence of hypokalemia in GepNET patients should prompt suspicion of EAS, espe-
cially when other symptoms such as hypertension, muscle weakness or weight loss appear.
2. GepNET patients usually do not have time to develop typical cushingoid feature because of
rapid progression of EAS.
3. Diagnosis of GepNET in EAS patients significantly worsens the probability of surviving.
4. In active searching for the source of ectopic cortisol production, combining different imag-
ining techniques allows to increase sensitivity. In patients with NET, SRS should be the test
of choice.
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zielania ACTH. Endokrynol Pol. 2015 Oct 29; 64(6):480–93.
2. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet (London, England).
2015 Aug 29; 386(9996):913–27.
3. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing’s Syndrome Due to Ectopic Corti-
cotropin Secretion: Twenty Years’ Experience at the National Institutes of Health. J Clin Endocrinol
Metab. 2005; 90(8):4955–62. https://doi.org/10.1210/jc.2004-2527 PMID: 15914534
4. Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol. 2007 Nov; 51(8):1217–25.
https://doi.org/10.1590/s0004-27302007000800007 PMID: 18209859
5. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet (London,
England). 2006 May 13; 367(9522):1605–17. https://doi.org/10.1016/S0140-6736(06)68699-6 PMID:
16698415
6. Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late
prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001 Jan; 86
(1):117–23. https://doi.org/10.1210/jcem.86.1.7093 PMID: 11231987
7. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syn-
drome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the
Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab. 1999 Feb; 84
(2):440–8. https://doi.org/10.1210/jcem.84.2.5465 PMID: 10022398
8. Orth DN. Cushing’s syndrome. N Engl J Med. 1995 Mar 23; 332(12):791–803. https://doi.org/10.1056/
NEJM199503233321207 PMID: 7862184
9. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, et al. Cushing syn-
drome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Ander-
son Cancer Center Experience. Cancer. 2011 Oct 1; 117(19):4381–9. https://doi.org/10.1002/cncr.
26029 PMID: 21412758
10. Aron DC, Raff H, Findling JW. Effectiveness Versus Efficacy: The Limited Value in Clinical Practice of
High Dose Dexamethasone Suppression Testing in the Differential Diagnosis of Adrenocorticotropin-
Dependent Cushing’s Syndrome. J Clin Endocrinol Metab. 1997 Jun 1; 82(6):1780–5. https://doi.org/
10.1210/jcem.82.6.3991 PMID: 9177382
11. Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, et al. Ectopic
adrenocorticotropic hormone syndrome. Endocr Rev. 1994 Dec; 15(6):752–87. https://doi.org/10.1210/
edrv-15-6-752 PMID: 7705280
12. LIDDLE GW, ISLAND DP, NEY RL, NICHOLSON WE, SHIMIZU N. Nonpituitary neoplasms and Cush-
ing’s syndrome. Ectopic “adrenocorticotropin” produced by nonpituitary neoplasms as a cause of Cush-
ing’s syndrome. Arch Intern Med. 1963 Apr; 111:471–5. https://doi.org/10.1001/archinte.1963.
03620280071011 PMID: 13930496
13. MEADOR CK, LIDDLE GW, ISLAND DP, NICHOLSON WE, LUCAS CP, NUCKTON JG, et al. Cause
of Cushing’s syndrome in patients with tumors arising from “nonendocrine” tissue. J Clin Endocrinol
Metab. 1962 Jul; 22(November):693–703. https://doi.org/10.1210/jcem-22-7-693 PMID: 14471915
14. Davi MV, Cosaro E, Piacentini S, Reimondo G, Albiger N, Arnaldi G, et al. Prognostic factors in ectopic
Cushing ‘ s syndrome due to neuroendocrine tumors: a multicenter study. 2017;
15. Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, et al. Mortality in Cush-
ing’s syndrome: Systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013;
169(5):715–23. https://doi.org/10.1530/EJE-13-0569 PMID: 23996696
16. Osswald A, Deutschbein T, Berr CM, Plomer E, Mickisch A, Ritzel K, et al. Surviving ectopic Cushing’s
syndrome: Quality of life, cardiovascular and metabolic outcomes in comparison to Cushing’s disease
during long-term follow-up. Eur J Endocrinol. 2018 Aug; 179(2):109–16. https://doi.org/10.1530/EJE-
18-0212 PMID: 29875286
PLOS ONE Ectopic ACTH syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0242679 November 25, 2020 16 / 19
17. Doppman JL, Nieman L, Miller DL, Pass HI, Chang R, Cutler GB, et al. Ectopic adrenocorticotropic hor-
mone syndrome: localization studies in 28 patients. Radiology. 1989 Jul; 172(1):115–24. https://doi.org/
10.1148/radiology.172.1.2544919 PMID: 2544919
18. Salgado LR, Villares Fragoso MCB, Knoepfelmacher M, Machado MC, Domenice S, Pereira MAA,
et al. Ectopic ACTH syndrome: Our experience with 25 cases. Eur J Endocrinol. 2006; 155(5):725–33.
https://doi.org/10.1530/eje.1.02278 PMID: 17062889
19. Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord. 2010 Jun; 11
(2):117–26. https://doi.org/10.1007/s11154-010-9139-z PMID: 20544290
20. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, et al. Petrosal sinus sampling
with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome.
N Engl J Med. 1991 Sep 26; 325(13):897–905. https://doi.org/10.1056/NEJM199109263251301
PMID: 1652686
21. Aniszewski JP, Young WF, Thompson GB, Grant CS, van Heerden JA. Cushing syndrome due to
ectopic adrenocorticotropic hormone secretion. World J Surg. 2001 Jul; 25(7):934–40. https://doi.org/
10.1007/s00268-001-0032-5 PMID: 11572035
22. Reimondo G, Paccotti P, Minetto M, Termine A, Stura G, Bergui M, et al. The corticotrophin-releasing
hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secre-
tion in Cushing’s syndrome. Clin Endocrinol (Oxf). 2003; 58(6):718–24. https://doi.org/10.1046/j.1365-
2265.2003.01776.x PMID: 12780748
23. Imura H, Matsukura S, Yamamoto H, Hirata Y, Nakai Y. Studies on ectopic ACTH-producing tumors. II.
Clinical and biochemical features of 30 cases. Cancer. 1975 May; 35(5):1430–7. https://doi.org/10.
1002/1097-0142(197505)35:5<1430::aid-cncr2820350529>3.0.co;2-o PMID: 164276
24. Ozbey N, Bozbora A, Kalayci G, Kapran Y, Yilmazbayhan D, Dizdaroglu F, et al. Cushing’s syndrome
caused by ectopic corticotropin secretion by multiple peripheral pulmonary carcinoids and tumorlets of
carcinoid type. J Endocrinol Invest. 2000 Sep 11; 23(8):536–41. https://doi.org/10.1007/BF03343771
PMID: 11021771
25. Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic
ACTH syndrome at a single institute in Japan. Endocr J. 2010; 57(12):1061–9. https://doi.org/10.1507/
endocrj.k10e-265 PMID: 21076235
26. Wajchenberg BL, Mendonça BB, Liberman B, Pereira MAA, Kirschner MA. Ectopic ACTH syndrome. J
Steroid Biochem Mol Biol. 1995 Jun 17; 53(1–6):139–51. https://doi.org/10.1016/0960-0760(95)00044-
z PMID: 7626446
27. Aljassem G, Aljasem H. Case report: Ectopic Cushing’s syndrome in a young male with hidden lung car-
cinoid tumor. Int J Surg Case Rep. 2018; 42:13–6. https://doi.org/10.1016/j.ijscr.2017.11.034 PMID:
29202350
28. Park SS, Kong SH, Yang YS, Ahn CH, Kim JH. Catatonia as a presenting symptom of ectopic adreno-
corticotropic hormone syndrome caused by thymic carcinoid tumor. Polish Arch Intern Med. 2018 Jun
29; 128(6):389–91. https://doi.org/10.20452/pamw.4285 PMID: 29968699
29. Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-
dependent Cushing’s syndrome: comparison of the features in ectopic and pituitary ACTH production.
Clin Endocrinol (Oxf). 1986 Jun; 24(6):699–713. https://doi.org/10.1111/j.1365-2265.1986.tb01667.x
PMID: 3024870
30. Kauffmann RM, Wang L, Phillips S, Idrees K, Merchant NB, Parikh AA. Incidence of Additional
Primary Malignancies in Patients with Pancreatic and Gastrointestinal Neuroendocrine Tumors.
2014;3422–8.
31. Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s
syndrome caused by ectopic ACTH secretion: A series of 58 cases. Ann N Y Acad Sci. 2002; 970:134–
44. https://doi.org/10.1111/j.1749-6632.2002.tb04419.x PMID: 12381548
32. Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, Venneri MA. The Immune System in
Cushing’s Syndrome. Trends Endocrinol Metab. 2020;1–15. https://doi.org/10.1016/j.tem.2019.11.002
PMID: 31767267
33. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in cushing syndrome
due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000; 85(1):42–7. https://doi.
org/10.1210/jcem.85.1.6294 PMID: 10634361
34. Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing’s syndrome. Ann Intern Med.
1984; 101(3):334–8. https://doi.org/10.7326/0003-4819-101-3-334 PMID: 6331781
35. Cho S, Sung S-W, Chung J-H, Lee C-T, Jheon S, Ra YJ. Difficulties in Diagnosis and Management of
Ectopic Cushing Syndrome. J Thorac Oncol. 2008; 3(4):444–6. https://doi.org/10.1097/JTO.
0b013e318169e316 PMID: 18379368
PLOS ONE Ectopic ACTH syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0242679 November 25, 2020 17 / 19
36. Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorti-
cotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocri-
nol Metab. 2006 Feb; 91(2):371–7. https://doi.org/10.1210/jc.2005-1542 PMID: 16303835
37. Biering H, Pirlich M, Bauditz J, Sandrock D, Lochs H, Gerl H. PET scan in occult ectopic ACTH syn-
drome: a useful tool? Clin Endocrinol (Oxf). 2003 Sep; 59(3):404–5. https://doi.org/10.1046/j.1365-
2265.2003.01853.x PMID: 12919167
38. Sathyakumar S, Paul TV, Asha HS, Gnanamuthu BR, Paul MJ, Abraham DT, et al. Ectopic cushing syn-
drome: A 10-year experience from a tertiary care center in southern India. Endocr Pract. 2017; 23
(8):907–14. https://doi.org/10.4158/EP161677.OR PMID: 28614007
39. Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969 Nov 1;
48(11):2096–103. https://doi.org/10.1172/JCI106176 PMID: 4980930
40. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol
Metab. 2009 Dec; 23(6):793–800. https://doi.org/10.1016/j.beem.2009.08.003 PMID: 19942154
41. Nicoloff JT, Fisher DA, Appleman MD. The role of glucocorticoids in the regulation of thyroid function in
man. J Clin Invest. 1970 Oct; 49(10):1922–9. https://doi.org/10.1172/JCI106411 PMID: 4990073
42. Mathioudakis N, Thapa S, Wand GS, Salvatori R. ACTH-secreting pituitary microadenomas are associ-
ated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin
Endocrinol (Oxf). 2012; https://doi.org/10.1111/j.1365-2265.2012.04442.x PMID: 22587880
43. Kamp K, Alwani RA, Korpershoek E, Franssen GJH, de Herder WW, Feelders RA. Prevalence and clin-
ical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuro-
endocrine tumors. Eur J Endocrinol. 2016 Mar; 174(3):271–80. https://doi.org/10.1530/EJE-15-0968
PMID: 26643855
44. Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, et al. Utility of various
functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting
tumors. J Clin Endocrinol Metab. 2010; 95(3):1207–19. https://doi.org/10.1210/jc.2009-2282 PMID:
20089611
45. Isidori AM, Sbardella E, Zatelli MC, Boschetti M, Vitale G, Colao A, et al. Conventional and Nuclear
Medicine Imaging in Ectopic Cushing’s Syndrome: A Systematic Review. J Clin Endocrinol Metab.
2015; 100(9):3231–44. https://doi.org/10.1210/JC.2015-1589 PMID: 26158607
46. Kumar J, Spring M, Carroll P V., Barrington SF, Powrie JK. 18Flurodeoxyglucose positron emission
tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol
(Oxf). 2006; 64(4):371–4. https://doi.org/10.1111/j.1365-2265.2006.02471.x PMID: 16584507
47. Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK. The Role of [18F]Fluorodeoxyglu-
cose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-D-Phe-Pentetreotide
Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing’s
Syndrome. J Clin Endocrinol Metab. 2004; 89(5):2214–21. https://doi.org/10.1210/jc.2003-031812
PMID: 15126544
48. Venkitaraman B, Karunanithi S, Kumar A, Bal C, Ammini AC, Kumar R. 68Ga-DOTATOC PET-CT in
the localization of source of ectopic ACTH in patients with ectopic ACTH-dependent Cushing’s syn-
drome. Clin Imaging. 2014 Mar; 38(2):208–11. https://doi.org/10.1016/j.clinimag.2013.10.007 PMID:
24332975
49. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somato-
statin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine
tumours: A meta-analysis. Endocrine. 2012; 42(1):80–7. https://doi.org/10.1007/s12020-012-9631-1
PMID: 22350660
50. Santhanam P, Taieb D, Giovanella L, Treglia G. PET imaging in ectopic Cushing syndrome: a system-
atic review. Endocrine. 2015 Nov 25; 50(2):297–305. https://doi.org/10.1007/s12020-015-0689-4
PMID: 26206753
51. Wannachalee T, Turcu AF, Bancos I, Habra MA, Avram AM, Chuang HH, et al. The Clinical Impact of
[68Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hor-
mone–Secreting Tumours. Clin Endocrinol (Oxf). 2019; 91(2):288–94.
52. de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, et al. Somatostatin
receptor scintigraphy: its value in tumor localization in patients with Cushing’s syndrome caused by
ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med. 1994 Apr; 96(4):305–12.
https://doi.org/10.1016/0002-9343(94)90059-0 PMID: 8166148
53. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendo-
crine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and
18F-FDG. Cancer. 2008 Jun; 112(11):2447–55. https://doi.org/10.1002/cncr.23469 PMID: 18383518
54. Raff H, Sharma ST, Nieman LK. Physiological Basis for the Etiology, Diagnosis, and Treatment of Adre-
nal Disorders: Cushing’s Syndrome, Adrenal Insufficiency, and Congenital Adrenal Hyperplasia. In:
PLOS ONE Ectopic ACTH syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0242679 November 25, 2020 18 / 19
Comprehensive Physiology. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2014. p. 739–69. https://doi.
org/10.1002/cphy.c130035 PMID: 24715566
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